

Supplementary material

Optimal synthesis conditions for NBF-modified 8,13-dihydroberberine derivatives

A. D. Zagrebaev^{1*}, V. V. Butova², A. A. Guda^{1*}, S. V. Chapek¹, O. N. Burov³, S. V. Kurbatov³, E. Yu. Vinyukova⁴, M. E. Neganova⁴, Yu. R. Aleksandrova⁴, N. S. Nikolaeva⁴, O. P. Demidov⁵, A. V. Soldatov¹

¹The Smart Materials Research Institute, Southern Federal University, 344090 Rostov-on-Don, Russia

²Institute of General and Inorganic Chemistry Bulgarian Academy of Sciences, Sofia, Bulgaria

³Faculty of Chemistry, Southern Federal University, 344090 Rostov-on-Don, Russia

⁴Institute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, Severnij Pr. 1, Chernogolovka 142432, Russia

⁵Department of Chemistry, North Caucasus Federal University, Pushkin st. 1, Stavropol, 355009, Russia

Table of contents

| | |
|---|----|
| Table S1. Optimization process table for batch synthesis, using derivative 9a as an example. | 5 |
| ¹ H NMR spectrum of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-phenylethan-1-one (4a) was obtained in CDCl ₃ | 6 |
| COSY NMR spectrum of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-phenylethan-1-one (4a) was obtained in CDCl ₃ | 7 |
| ¹³ C NMR spectrum of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-phenylethan-1-one (4a) was obtained in CDCl ₃ | 8 |
| The high-resolution mass spectrum (HRMS) of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-phenylethan-1-one (4a). | 9 |
| ATR spectrum of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-phenylethan-1-one (4a). | 11 |
| UV-Vis spectrum of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-phenylethan-1-one (4a) dissolved in DMF (Absorbance (A), a. u.), at a concentration of 1*10 ⁻⁴ mol/L..... | 12 |
| UV-Vis spectrum of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-phenylethan-1-one (4a) dissolved in DMF (Transmittance (T), %), at a concentration of 1*10 ⁻⁴ mol/L..... | 13 |
| ¹ H NMR spectrum of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-(p-tolyl)ethan-1-one (5a) was obtained in CDCl ₃ | 14 |
| ¹³ C NMR spectrum of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-(p-tolyl)ethan-1-one (5a) was obtained in CDCl ₃ | 15 |
| The high-resolution mass spectrum (HRMS) of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-(p-tolyl)ethan-1-one (5a). | 16 |
| ATR spectrum of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-(p-tolyl)ethan-1-one (5a). | 18 |
| UV-Vis spectrum of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-(p-tolyl)ethan-1-one (5a) dissolved in DMF (Absorbance (A), a. u.), at a concentration of 1*10 ⁻⁴ mol/L | 19 |
| UV-Vis spectrum of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-(p-tolyl)ethan-1-one (5a) dissolved in DMF (Transmittance (T), %), at a concentration of 1*10 ⁻⁴ mol/L..... | 20 |
| ¹ H NMR spectrum of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-(4-methoxyphenyl)ethan-1-one (6a) was obtained in CDCl ₃ | 21 |
| ¹³ C NMR spectrum of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-(4-methoxyphenyl)ethan-1-one (6a) was obtained in CDCl ₃ | 22 |
| The high-resolution mass spectrum (HRMS) of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-(4-methoxyphenyl)ethan-1-one (6a). | 23 |

| | |
|---|----|
| ATR spectrum of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-(4-methoxyphenyl)ethan-1-one (6a) | 25 |
| UV-Vis spectrum of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-(4-methoxyphenyl)ethan-1-one (6a) dissolved in DMF (Absorbance (A), a. u.), at a concentration of 1×10^{-4} mol/L | 26 |
| UV-Vis spectrum of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-(4-methoxyphenyl)ethan-1-one (6a) dissolved in DMF (Transmittance (T), %), at a concentration of 1×10^{-4} mol/L..... | 27 |
| ¹ H NMR spectrum of 1-(4-aminophenyl)-2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)ethan-1-one (7a) was obtained in CDCl ₃ | 28 |
| ¹ H NMR spectrum of 1-(4-aminophenyl)-2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)ethan-1-one (7a) was acquired in CDCl ₃ with D ₂ O..... | 29 |
| ¹³ C NMR spectrum of 1-(4-aminophenyl)-2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)ethan-1-one (7a) was obtained in CDCl ₃ | 30 |
| The high-resolution mass spectrum (HRMS) of 1-(4-aminophenyl)-2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)ethan-1-one (7a)..... | 31 |
| ATR spectrum of 1-(4-aminophenyl)-2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)ethan-1-one (7a). | 33 |
| UV-Vis spectrum of 1-(4-aminophenyl)-2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)ethan-1-one (7a) dissolved in DMF (Absorbance (A), a. u.), at a concentration of 1×10^{-4} mol/L | 34 |
| UV-Vis spectrum of 1-(4-aminophenyl)-2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)ethan-1-one (7a) dissolved in DMF (Transmittance (T), %), at a concentration of 1×10^{-4} mol/L..... | 35 |
| ¹ H NMR spectrum of 1-(4-chlorophenyl)-2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)ethan-1-one (8a) was obtained in CDCl ₃ | 36 |
| ¹³ C NMR spectrum of 1-(4-chlorophenyl)-2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)ethan-1-one (8a) was obtained in CDCl ₃ | 37 |
| The high-resolution mass spectrum (HRMS) of 1-(4-chlorophenyl)-2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)ethan-1-one (8a). | 38 |
| ATR spectrum of 1-(4-chlorophenyl)-2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)ethan-1-one (8a). | 40 |
| UV-Vis spectrum of 1-(4-chlorophenyl)-2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl) ethan-1-one (8a) dissolved in DMF (Absorbance (A), a. u.), at a concentration of 1×10^{-4} mol/L | 41 |
| UV-Vis spectrum of 1-(4-chlorophenyl)-2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)ethan-1-one (8a) dissolved in DMF (Transmittance (T), %), at a concentration of 1×10^{-4} mol/L..... | 42 |

| | |
|--|----|
| ¹ H NMR spectrum of 1-(4-bromophenyl)-2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)ethan-1-one (9a) was obtained in CDCl ₃ | 43 |
| ¹³ C NMR spectrum of 1-(4-bromophenyl)-2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)ethan-1-one (9a) was obtained in CDCl ₃ | 44 |
| The high-resolution mass spectrum (HRMS) of 1-(4-bromophenyl)-2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)ethan-1-one (9a). | 45 |
| ATR spectrum of 1-(4-bromophenyl)-2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)ethan-1-one (9a). | 47 |
| UV-Vis spectrum of 1-(4-bromophenyl)-2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)ethan-1-one (9a) dissolved in DMF (Absorbance (A), a. u.), at a concentration of 1*10 ⁻⁴ mol/L. | 48 |
| UV-Vis spectrum of 1-(4-bromophenyl)-2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)ethan-1-one (9a) dissolved in DMF (Transmittance (T), %), at a concentration of 1*10 ⁻⁴ mol/L. | 49 |
| ¹ H NMR spectrum of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-(4-nitrophenyl)ethan-1-one (10a) was obtained in CDCl ₃ | 50 |
| ¹³ C NMR spectrum of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-(4-nitrophenyl)ethan-1-one (10a) was obtained in CDCl ₃ | 51 |
| The high-resolution mass spectrum (HRMS) of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-(4-nitrophenyl)ethan-1-one (10a). | 52 |
| ATR spectrum of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-(4-nitrophenyl)ethan-1-one (10a). | 54 |
| UV-Vis spectrum of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-(4-nitrophenyl)ethan-1-one (10a) dissolved in DMF (Absorbance (A), a. u.), at a concentration of 1*10 ⁻⁴ mol/L. | 55 |
| UV-Vis spectrum of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-(4-nitrophenyl)ethan-1-one (10a) dissolved in DMF (Transmittance (T), %), at a concentration of 1*10 ⁻⁴ mol/L. | 56 |
| ¹ H NMR spectrum of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-(pyridin-4-yl)ethan-1-one (11a) was obtained in CDCl ₃ | 57 |
| ¹³ C NMR spectrum of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-(pyridin-4-yl)ethan-1-one (11a) was obtained in CDCl ₃ | 58 |
| The high-resolution mass spectrum (HRMS) of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-(pyridin-4-yl)ethan-1-one (11a). | 59 |
| ATR spectrum of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-(pyridin-4-yl)ethan-1-one (11a). | 61 |

UV-Vis spectrum of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-(pyridin-4-yl)ethan-1-one (**11a**) dissolved in DMF (Absorbance (A), a. u.), at a concentration of 1×10^{-4} mol/L 62

UV-Vis spectrum of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-(pyridin-4-yl)ethan-1-one (**11a**) dissolved in DMF (Transmittance (T), %), at a concentration of 1×10^{-4} mol/L 63

Table S1. Optimization process table for batch synthesis, using derivative **9a** as an example.

| Solvent | Acetone** | Benzene | CH ₃ CN | DMF | CHCl ₃ |
|--------------------------------|-----------|---------|--------------------|-----|---------------------------------|
| Temperature*, °C | 5 | | | | |
| Yield of the target product, % | 32 | 42 | 45 | 63 | - |
| Temperature*, °C | 25 | | | | |
| Yield of the target product, % | 24 | 55 | 55 | 66 | 15 |
| Temperature*, °C | 50 | | | | |
| Yield of the target product, % | <10 | 34 | - | 30 | Degradation of reaction mixture |


*With further increases in reaction temperature, there is a consistent decrease in the yield of the reaction product. When the temperature exceeds 70°C in any solvent, the reaction mixture goes through complete degradation.

** In the synthesis conditions, acetone acts as a competing reagent and has the potential to substitute the functional group at position C-8. This substitution results in reduced yields of the desired products when the temperature is increased.


The determination of temperature and solvation effects (Table S1) was conducted under batch conditions. Low-temperature conditions were achieved using a refrigeration chamber, and reaction temperature was controlled using a thermocouple. Room temperature conditions and heating were controlled using an oil bath with a thermocouple.

A measured amount of reduced form berberine (DHB) (1 mmol) was dissolved in 15 mL of the appropriate solvent (in the case of benzene, the solution needed to be heated to accelerate the dissolution process) with stirring. To this solution, 1 mmol of triethylamine (TEA) was added. Separately, 1 mmol of chloronitrobenzofurazane (NBF-Cl) was dissolved in 15 mL of chilled appropriate solvent and slowly added to the solution of activated form berberine (DHB) while continuously stirring. The reaction mixture was stirred in the dark for 2 hours. Then, the solution was separated, analyzed by ¹H spectroscopy, and the product yield was evaluated based on the results of weighing.


¹H NMR spectrum of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-phenylethan-1-one (**4a**) was obtained in CDCl₃.



COSY NMR spectrum of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-phenylethan-1-one (**4a**) was obtained in CDCl_3 .



¹³C NMR spectrum of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-phenylethan-1-one (**4a**) was obtained in CDCl₃.



The high-resolution mass spectrum (HRMS) of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-phenylethan-1-one (**4a**).




Display Report

Analysis Info

| | | | |
|---------------|-------------------------------|------------------|---------------------------|
| Analysis Name | D:\Data\demidov\Dem2a000001.d | Acquisition Date | 7/18/2023 1:33:48 PM |
| Method | Tune_pos_Standard23.m | Operator | Demidov |
| Sample Name | 1 | Instrument | maXis impact 282001.00109 |
| Comment | | | |

Acquisition Parameter

| | | | | | |
|-------------|----------|-----------------------|-----------|------------------|-----------|
| Source Type | ESI | Ion Polarity | Positive | Set Nebulizer | 0.3 Bar |
| Focus | Active | Set Capillary | 4000 V | Set Dry Heater | 220 °C |
| Scan Begin | 50 m/z | Set End Plate Offset | -500 V | Set Dry Gas | 4.0 l/min |
| Scan End | 1111 m/z | Set Collision Cell RF | 500.0 Vpp | Set Divert Valve | Source |




Display Report


| Meas. | m/z | # | Ion Formula | m/z | err [ppm] | mSigma | Score | rdb | e ⁻ | Conf | N-Rule |
|----------|-----|--------------|-------------|------|-----------|--------|--------|------|----------------|------|--------|
| 499.1256 | 1 | C27H15N8O3 | 499.1262 | 1.1 | 23.1 | 2 | 90.76 | 24.5 | even | ok | |
| | 2 | C26H19N4O7 | 499.1248 | -1.6 | 11.6 | 1 | 100.00 | 19.5 | even | ok | |
| | 1 | C29H20N2NaO5 | 499.1264 | 1.6 | 23.9 | 2 | 100.00 | 20.5 | even | ok | |
| | 2 | C25H16N8NaO3 | 499.1238 | -3.8 | 12.4 | 1 | 64.58 | 21.5 | even | ok | |
| | 1 | C23H16KN12 | 499.1252 | -0.8 | 32.6 | 2 | 100.00 | 21.5 | even | ok | |
| | 2 | C26H24KN2O6 | 499.1266 | 1.9 | 34.5 | 3 | 88.64 | 15.5 | even | ok | |
| | 3 | C22H20KN8O4 | 499.1239 | -3.5 | 29.0 | 1 | 62.61 | 16.5 | even | ok | |
| | 1 | C27H15N8O3 | 499.1262 | 1.1 | 23.1 | 2 | 90.76 | 24.5 | even | ok | |
| 641.1646 | 2 | C26H19N4O7 | 499.1248 | -1.6 | 11.6 | 1 | 100.00 | 19.5 | even | ok | |
| | 1 | C34H26N4NaO8 | 641.1643 | -0.6 | 4.0 | 1 | 100.00 | 23.5 | even | ok | |
| | 2 | C35H22N8NaO4 | 641.1656 | 1.5 | 15.5 | 2 | 58.88 | 28.5 | even | ok | |

+MS, 0.1-0.1min #3-6


ATR spectrum of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-phenylethan-1-one (**4a**).




UV-Vis spectrum of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-phenylethan-1-one (4a) dissolved in DMF (Absorbance (A), a. u.), at a concentration of 1×10^{-4} mol/L.




UV-Vis spectrum of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-phenylethan-1-one (4a) dissolved in DMF (Transmittance (T), %), at a concentration of 1×10^{-4} mol/L.



¹H NMR spectrum of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-(p-tolyl)ethan-1-one (**5a**) was obtained in CDCl₃



¹³C NMR spectrum of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-(p-tolyl)ethan-1-one (**5a**) was obtained in CDCl₃.



The high-resolution mass spectrum (HRMS) of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-(p-tolyl)ethan-1-one (**5a**).




Display Report

Analysis Info

| | | | |
|---------------|-------------------------------|------------------|---------------------------|
| Analysis Name | D:\Data\demidov\Dem3a000001.d | Acquisition Date | 7/18/2023 12:52:04 PM |
| Method | Tune_pos_Standard23.m | Operator | Demidov |
| Sample Name | 1 | Instrument | maXis impact 282001.00109 |
| Comment | | | |

Acquisition Parameter

| | | | | | |
|-------------|----------|-----------------------|-----------|------------------|-----------|
| Source Type | ESI | Ion Polarity | Positive | Set Nebulizer | 0.3 Bar |
| Focus | Active | Set Capillary | 4000 V | Set Dry Heater | 220 °C |
| Scan Begin | 50 m/z | Set End Plate Offset | -500 V | Set Dry Gas | 4.0 l/min |
| Scan End | 1111 m/z | Set Collision Cell RF | 500.0 Vpp | Set Divert Valve | Source |




Display Report


| Meas. m/z | # | Ion Formula | m/z | err [ppm] | mSigma | Score | rdb | e ⁻ Conf | N-Rule |
|-----------|---|--------------|----------|-----------|--------|-------|--------|---------------------|--------|
| 655.1797 | 1 | C36H31O12 | 655.1810 | 2.0 | 1.8 | 1 | 100.00 | 21.5 even | ok |
| | 1 | C35H28N4NaO8 | 655.1799 | 0.4 | 4.6 | 1 | 100.00 | 23.5 even | ok |
| | 1 | C44H28KN2O2 | 655.1782 | -2.2 | 58.2 | 1 | 100.00 | 31.5 even | ok |

+MS, 0.1-0.1min #3-6


ATR spectrum of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-(p-tolyl)ethan-1-one (**5a**).




UV-Vis spectrum of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-(p-tolyl)ethan-1-one (5a**) dissolved in DMF (Absorbance (A), a. u.), at a concentration of 1×10^{-4} mol/L.**




UV-Vis spectrum of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-(p-tolyl)ethan-1-one (5a) dissolved in DMF (Transmittance (T), %), at a concentration of 1×10^{-4} mol/L.



¹H NMR spectrum of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-(4-methoxyphenyl)ethan-1-one (**6a**) was obtained in CDCl₃



C^{13} NMR spectrum of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-(4-methoxyphenyl)ethan-1-one (**6a**) was obtained in CDCl_3 .



The high-resolution mass spectrum (HRMS) of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-(4-methoxyphenyl)ethan-1-one (**6a**).




Display Report

Analysis Info

| | | | |
|---------------|-------------------------------|------------------|---------------------------|
| Analysis Name | D:\Data\demidov\Dem4a000001.d | Acquisition Date | 7/18/2023 1:47:49 PM |
| Method | Tune_pos_Standard23.m | Operator | Demidov |
| Sample Name | 1 | Instrument | maXis impact 282001.00109 |
| Comment | | | |

Acquisition Parameter

| | | | | | |
|-------------|----------|-----------------------|-----------|------------------|-----------|
| Source Type | ESI | Ion Polarity | Positive | Set Nebulizer | 0.3 Bar |
| Focus | Active | Set Capillary | 4000 V | Set Dry Heater | 220 °C |
| Scan Begin | 50 m/z | Set End Plate Offset | -500 V | Set Dry Gas | 4.0 l/min |
| Scan End | 1111 m/z | Set Collision Cell RF | 500.0 Vpp | Set Divert Valve | Source |




Display Report


| Meas. | m/z | # | Ion Formula | m/z | err [ppm] | mSigma | Score | rdb | e ⁻ | Conf | N-Rule |
|-------|----------|---|--------------|----------|-----------|--------|-------|--------|----------------|------|--------|
| | 671.1755 | 1 | C37H27N4O9 | 671.1773 | 2.6 | 5.4 | 1 | 100.00 | 26.5 | even | ok |
| | | 1 | C35H28N4NaO9 | 671.1748 | -0.9 | 7.4 | 1 | 100.00 | 23.5 | even | ok |
| | | 2 | C36H24N8NaO5 | 671.1762 | 1.1 | 7.8 | 2 | 95.42 | 28.5 | even | ok |

+MS, 0.1-0.1min #3-7


ATR spectrum of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-(4-methoxyphenyl)ethan-1-one (**6a**).




UV-Vis spectrum of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-(4-methoxyphenyl)ethan-1-one (6a**) dissolved in DMF (Absorbance (A), a. u.), at a concentration of 1×10^{-4} mol/L.**




UV-Vis spectrum of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-(4-methoxyphenyl)ethan-1-one (6a) dissolved in DMF (Transmittance (T), %), at a concentration of 1×10^{-4} mol/L.




¹H NMR spectrum of 1-(4-aminophenyl)-2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)ethan-1-one (**7a**) was obtained in CDCl₃



¹H NMR spectrum of 1-(4-aminophenyl)-2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)ethan-1-one (**7a**) was acquired in CDCl₃ with D₂O.



¹³C NMR spectrum of 1-(4-aminophenyl)-2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)ethan-1-one (**7a**) was obtained in CDCl₃.



The high-resolution mass spectrum (HRMS) of 1-(4-aminophenyl)-2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)ethan-1-one (**7a**).




Display Report

Analysis Info

| | | | |
|---------------|-------------------------------|------------------|---------------------------|
| Analysis Name | D:\Data\demidov\Dem5a000001.d | Acquisition Date | 7/18/2023 1:16:52 PM |
| Method | Tune_pos_Standard23.m | Operator | Demidov |
| Sample Name | 1 | Instrument | maXis impact 282001.00109 |
| Comment | | | |

Acquisition Parameter

| | | | | | |
|-------------|----------|-----------------------|-----------|------------------|-----------|
| Source Type | ESI | Ion Polarity | Positive | Set Nebulizer | 0.3 Bar |
| Focus | Active | Set Capillary | 4000 V | Set Dry Heater | 220 °C |
| Scan Begin | 50 m/z | Set End Plate Offset | -500 V | Set Dry Gas | 4.0 l/min |
| Scan End | 1111 m/z | Set Collision Cell RF | 500.0 Vpp | Set Divert Valve | Source |




Display Report


| Meas. | m/z | # | Ion Formula | m/z | err [ppm] | mSigma | Score | rdb | e ⁻ Conf | N-Rule |
|-------|----------|---|--------------|----------|-----------|--------|-------|--------|---------------------|--------|
| | 656.1757 | 1 | C35H30NO12 | 656.1763 | 0.9 | 2.4 | 1 | 100.00 | 21.5 even | ok |
| | | 1 | C34H27N5NaO8 | 656.1752 | -0.7 | 2.9 | 1 | 100.00 | 23.5 even | ok |
| | | 1 | C48H27KN | 656.1775 | 2.8 | 79.7 | 1 | 100.00 | 35.5 even | ok |

+MS, 0.1-0.1min #3-5


ATR spectrum of 1-(4-aminophenyl)-2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)ethan-1-one (**7a**).




UV-Vis spectrum of 1-(4-aminophenyl)-2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)ethan-1-one (7a) dissolved in DMF (Absorbance (A), a. u.), at a concentration of 1×10^{-4} mol/L.




UV-Vis spectrum of 1-(4-aminophenyl)-2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)ethan-1-one (7a) dissolved in DMF (Transmittance (T), %), at a concentration of 1×10^{-4} mol/L.



¹H NMR spectrum of 1-(4-chlorophenyl)-2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)ethan-1-one (**8a**) was obtained in CDCl₃



¹³C NMR spectrum of 1-(4-chlorophenyl)-2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)ethan-1-one (**8a**) was obtained in CDCl₃.



The high-resolution mass spectrum (HRMS) of 1-(4-chlorophenyl)-2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)ethan-1-one (**8a**).




Display Report

Analysis Info

| | | | |
|---------------|-------------------------------|------------------|---------------------------|
| Analysis Name | D:\Data\demidov\Dem8a000001.d | Acquisition Date | 7/18/2023 1:00:00 PM |
| Method | Tune_pos_Standard23.m | Operator | Demidov |
| Sample Name | 1 | Instrument | maXis impact 282001.00109 |
| Comment | | | |

Acquisition Parameter

| | | | | | |
|-------------|----------|-----------------------|-----------|------------------|-----------|
| Source Type | ESI | Ion Polarity | Positive | Set Nebulizer | 0.3 Bar |
| Focus | Active | Set Capillary | 4000 V | Set Dry Heater | 220 °C |
| Scan Begin | 50 m/z | Set End Plate Offset | -500 V | Set Dry Gas | 4.0 l/min |
| Scan End | 1111 m/z | Set Collision Cell RF | 500.0 Vpp | Set Divert Valve | Source |




Display Report


| Meas. m/z | # | Ion Formula | m/z | err [ppm] | mSigma | Score | rdb | e ⁻ Conf | N-Rule |
|-----------|---|---------------|----------|-----------|--------|-------|--------|---------------------|---------|
| 686.1501 | 1 | C35H28NO14 | 686.1504 | 0.5 | 18.5 | 1 | 100.00 | 22.5 | even ok |
| | 1 | C34H25N5NaO10 | 686.1494 | -1.1 | 18.9 | 1 | 100.00 | 24.5 | even ok |
| | 1 | C48H25KNO2 | 686.1517 | 2.3 | 66.1 | 1 | 100.00 | 36.5 | even ok |

+MS, 0.0-0.1min #2-6


ATR spectrum of 1-(4-chlorophenyl)-2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)ethan-1-one (**8a**).




UV-Vis spectrum of 1-(4-chlorophenyl)-2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl) ethan-1-one (8a) dissolved in DMF (Absorbance (A), a. u.), at a concentration of 1×10^{-4} mol/L.




UV-Vis spectrum of 1-(4-chlorophenyl)-2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)ethan-1-one (8a) dissolved in DMF (Transmittance (T), %), at a concentration of 1×10^{-4} mol/L.



¹H NMR spectrum of 1-(4-bromophenyl)-2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)ethan-1-one (**9a**) was obtained in CDCl₃



¹³C NMR spectrum of 1-(4-bromophenyl)-2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)ethan-1-one (**9a**) was obtained in CDCl₃.



The high-resolution mass spectrum (HRMS) of 1-(4-bromophenyl)-2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)ethan-1-one (**9a**).




Display Report

Analysis Info

| | | | |
|---------------|-------------------------------|------------------|---------------------------|
| Analysis Name | D:\Data\demidov\Dem7a000002.d | Acquisition Date | 7/18/2023 1:25:35 PM |
| Method | Tune_pos_Standard23.m | Operator | Demidov |
| Sample Name | 1 | Instrument | maXis impact 282001.00109 |
| Comment | | | |

Acquisition Parameter

| | | | | | |
|-------------|----------|-----------------------|-----------|------------------|-----------|
| Source Type | ESI | Ion Polarity | Positive | Set Nebulizer | 0.3 Bar |
| Focus | Active | Set Capillary | 4000 V | Set Dry Heater | 220 °C |
| Scan Begin | 50 m/z | Set End Plate Offset | -500 V | Set Dry Gas | 4.0 l/min |
| Scan End | 1111 m/z | Set Collision Cell RF | 500.0 Vpp | Set Divert Valve | Source |




Display Report


| Meas. m/z | # | Ion Formula | m/z | err [ppm] | mSigma | Score | rdb | e ⁻ | Conf | N-Rule |
|-----------|---------------|------------------|----------|-----------|--------|--------|--------|----------------|------|--------|
| 719.0750 | 1 | C35H28BrO12 | 719.0759 | 1.2 | 31.8 | 1 | 100.00 | 21.5 | even | ok |
| | 1 | C34H25BrN4NaO8 | 719.0748 | -0.3 | 29.7 | 1 | 100.00 | 23.5 | even | ok |
| 720.0783 | 1 | C40H28BrKNO5 | 720.0782 | -0.1 | 406.5 | 1 | 100.00 | 26.5 | even | ok |
| 721.0735 | 1 | C43H31Br2O | 721.0736 | 0.1 | 457.6 | 4 | 0.00 | 27.5 | even | ok |
| | 2 | C30H44Br3O5 | 721.0733 | -0.3 | 543.3 | 5 | 0.00 | 7.5 | even | ok |
| | 3 | C27H31Br2N8O6 | 721.0728 | -1.0 | 436.8 | 2 | 0.06 | 15.5 | even | ok |
| | 4 | C31H40Br3N4O | 721.0747 | 1.6 | 545.8 | 6 | 0.00 | 12.5 | even | ok |
| | 5 | C26H30BrN2O17 | 721.0722 | -1.8 | 391.2 | 1 | 100.00 | 12.5 | even | ok |
| | 6 | C31H35Br2N2O8 | 721.0755 | 2.7 | 440.5 | 3 | 0.02 | 14.5 | even | ok |
| 1 | C29H31BrNaO15 | 721.0739 | 0.4 | 393.4 | 1 | 100.00 | 13.5 | even | ok | |
| | 2 | C29H36Br2N2NaO8 | 721.0731 | -0.6 | 437.6 | 3 | 0.05 | 11.5 | even | ok |
| | 3 | C30H32Br2N6NaO4 | 721.0744 | 1.2 | 439.3 | 4 | 0.03 | 16.5 | even | ok |
| | 4 | C29H41Br3N4NaO | 721.0723 | -1.7 | 543.7 | 6 | 0.00 | 9.5 | even | ok |
| | 5 | C30H27BrN4NaO11 | 721.0752 | 2.3 | 395.6 | 2 | 32.72 | 18.5 | even | ok |
| | 6 | C26H28Br2N12NaO2 | 721.0717 | -2.5 | 465.8 | 5 | 0.00 | 17.5 | even | ok |
| | 1 | C39H27BrKN2O5 | 721.0735 | -0.1 | 382.9 | 3 | 10.28 | 26.5 | even | ok |
| | 2 | C26H40Br2KN2O9 | 721.0732 | -0.4 | 446.3 | 4 | 0.00 | 6.5 | even | ok |
| | 3 | C26H35BrKO16 | 721.0740 | 0.7 | 366.7 | 1 | 100.00 | 8.5 | even | ok |
| | 4 | C27H36Br2KN6O5 | 721.0746 | 1.4 | 447.8 | 5 | 0.00 | 11.5 | even | ok |
| | 5 | C26H45Br3KN4O2 | 721.0724 | -1.5 | 511.6 | 6 | 0.00 | 4.5 | even | ok |
| | 6 | C27H31BrKN4O12 | 721.0753 | 2.5 | 368.2 | 2 | 36.21 | 13.5 | even | ok |
| 1 | C27H31Br2N8O6 | 721.0728 | -1.0 | 436.8 | 1 | 100.00 | 15.5 | even | ok | |
| | 2 | C31H40Br3N4O | 721.0747 | 1.6 | 545.8 | 3 | 0.00 | 12.5 | even | ok |
| | 3 | C31H35Br2N2O8 | 721.0755 | 2.7 | 440.5 | 2 | 24.48 | 14.5 | even | ok |

+MS, 0.1-0.1min #3-5


ATR spectrum of 1-(4-bromophenyl)-2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)ethan-1-one (**9a**).




UV-Vis spectrum of 1-(4-bromophenyl)-2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)ethan-1-one (9a) dissolved in DMF (Absorbance (A), a. u.), at a concentration of 1×10^{-4} mol/L.




UV-Vis spectrum of 1-(4-bromophenyl)-2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)ethan-1-one (9a) dissolved in DMF (Transmittance (T), %), at a concentration of 1×10^{-4} mol/L.



¹H NMR spectrum of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-(4-nitrophenyl)ethan-1-one (**10a**) was obtained in CDCl₃



¹³C NMR spectrum of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-(4-nitrophenyl)ethan-1-one (**10a**) was obtained in CDCl₃.



The high-resolution mass spectrum (HRMS) of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-(4-nitrophenyl)ethan-1-one (**10a**).




Display Report

Analysis Info

| | | | |
|---------------|-------------------------------|------------------|---------------------------|
| Analysis Name | D:\Data\demidov\Dem8a000001.d | Acquisition Date | 7/18/2023 1:00:00 PM |
| Method | Tune_pos_Standard23.m | Operator | Demidov |
| Sample Name | 1 | Instrument | maXis impact 282001.00109 |
| Comment | | | |

Acquisition Parameter

| | | | | | |
|-------------|----------|-----------------------|-----------|------------------|-----------|
| Source Type | ESI | Ion Polarity | Positive | Set Nebulizer | 0.3 Bar |
| Focus | Active | Set Capillary | 4000 V | Set Dry Heater | 220 °C |
| Scan Begin | 50 m/z | Set End Plate Offset | -500 V | Set Dry Gas | 4.0 l/min |
| Scan End | 1111 m/z | Set Collision Cell RF | 500.0 Vpp | Set Divert Valve | Source |




Display Report


| Meas. m/z | # | Ion Formula | m/z | err [ppm] | mSigma | Score | rdb | e ⁻ | Conf | N-Rule |
|-----------|---|---------------|----------|-----------|--------|-------|--------|----------------|------|--------|
| 686.1501 | 1 | C35H28NO14 | 686.1504 | 0.5 | 18.5 | 1 | 100.00 | 22.5 | even | ok |
| | 1 | C34H25N5NaO10 | 686.1494 | -1.1 | 18.9 | 1 | 100.00 | 24.5 | even | ok |
| | 1 | C48H25KNO2 | 686.1517 | 2.3 | 66.1 | 1 | 100.00 | 36.5 | even | ok |

+MS, 0.0-0.1min #2-6


ATR spectrum of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-(4-nitrophenyl)ethan-1-one (**10a**).




UV-Vis spectrum of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-(4-nitrophenyl)ethan-1-one (10a**) dissolved in DMF (Absorbance (A), a. u.), at a concentration of 1×10^{-4} mol/L.**




UV-Vis spectrum of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-(4-nitrophenyl)ethan-1-one (10a) dissolved in DMF (Transmittance (T), %), at a concentration of 1×10^{-4} mol/L.



¹H NMR spectrum of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-(pyridin-4-yl)ethan-1-one (**11a**) was obtained in CDCl₃



¹³C NMR spectrum of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-(pyridin-4-yl)ethan-1-one (**11a**) was obtained in CDCl₃.



The high-resolution mass spectrum (HRMS) of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-(pyridin-4-yl)ethan-1-one (**11a**).




Display Report

Analysis Info

| | | | |
|---------------|-------------------------------|------------------|---------------------------|
| Analysis Name | D:\Data\demidov\Dem9a000003.d | Acquisition Date | 7/18/2023 1:53:44 PM |
| Method | Tune_pos_Standard23.m | Operator | Demidov |
| Sample Name | 1 | Instrument | maXis impact 282001.00109 |
| Comment | | | |

Acquisition Parameter

| | | | | | |
|-------------|----------|-----------------------|-----------|------------------|-----------|
| Source Type | ESI | Ion Polarity | Positive | Set Nebulizer | 0.3 Bar |
| Focus | Active | Set Capillary | 4000 V | Set Dry Heater | 220 °C |
| Scan Begin | 50 m/z | Set End Plate Offset | -500 V | Set Dry Gas | 4.0 l/min |
| Scan End | 1111 m/z | Set Collision Cell RF | 500.0 Vpp | Set Divert Valve | Source |




Display Report


| Meas. m/z | # | Ion Formula | m/z | err [ppm] | mSigma | Score | rdb | e ⁻ | Conf | N-Rule |
|-----------|---|--------------|----------|-----------|--------|-------|--------|----------------|------|--------|
| 642.1600 | 1 | C35H24N5O8 | 642.1619 | 3.0 | 16.1 | 1 | 100.00 | 26.5 | even | ok |
| | 1 | C33H25N5NaO8 | 642.1595 | -0.8 | 8.6 | 1 | 100.00 | 23.5 | even | ok |
| | 2 | C34H21N9NaO4 | 642.1609 | 1.3 | 18.1 | 2 | 69.38 | 28.5 | even | ok |

+MS, 0.1-0.1min #3-5

ATR spectrum of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-(pyridin-4-yl)ethan-1-one (**11a**).



UV-Vis spectrum of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-(pyridin-4-yl)ethan-1-one (11a**) dissolved in DMF (Absorbance (A), a. u.), at a concentration of 1×10^{-4} mol/L.**



UV-Vis spectrum of 2-(9,10-dimethoxy-13-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-5,8-dihydro-6H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-yl)-1-(pyridin-4-yl)ethan-1-one (**11a**) dissolved in DMF (Transmittance (T), %), at a concentration of 1×10^{-4} mol/L.

